NEURALTIDE
Karine Berthet is a seasoned professional in the medical field, currently serving as Co-Founder and CEO of Neuraltide since October 2017, where the focus is on developing a medical device for treating acute ischemic stroke. Karine has extensive experience at Pfizer, holding the position of Director of Clinical Sciences in the Pfizer PGRD since May 2015, and previously worked as European Medical Manager for the launch of Vyndaqel from June 2011 to June 2014, as well as European Medical Manager for Aricept from November 2004 to April 2011. Karine began their career as a Medical Manager for Relpax and the launch of Macugen. Academic credentials include a Doctor of Medicine from Université Paris Cité, a certification by the French Board of Neurology from University Paris 5, and a Medical Doctor license from University Paris V.
This person is not in any teams
NEURALTIDE
NEURALTIDE is dedicated to the development of a medical device for the treatment of ischemic strokes. Our goal is to provide a device that is non-invasive and easy to use, available in all types of hospitals, clinics or treatment centres requiring no additional skills for paramedical staff.